Connect your AI

Kura Oncology KURA Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

ExelixisEXEL

——

Arcus BiosciencesRCUS

——

Segments

By product

Commercialization Services$273.7M—

Other financials

Income statement

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Kura Oncology's accrued progress collections and price adjustments?: Kura Oncology (KURA) reported accrued progress collections and price adjustments of $416.75M in Q1 2026.
How has Kura Oncology's accrued progress collections and price adjustments changed year-over-year?: Kura Oncology's accrued progress collections and price adjustments increased by 53.3% year-over-year, from $271.93M to $416.75M.